Evaluation of intratumoral expression of chemotherapy-associated biomarkers for postoperative adjuvant chemotherarpy against advanced stage lung cancer

Evaluation of intratumoral expression of chemotherapy-associated biomarkers for postoperative adjuvant chemotherarpy against advanced stage lung cancer - Evaluation of expression of chemotherapy-associated biomarkers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039021

Enrollment

Registered

2020-02-20

Start date

2020-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Evaluation of chemotherapy-associated biomarkes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) pathologically diagnosed as advanced stage (stage II to III) non-small cell lung cancer 2) completely resected by surgery 3) under 75 years-old with PS 0 to 2, more than 74 years-old with PS 0 to1 4) laboratory data with 14 days before registration (1) neutrolophil count > 1,500 /mm3 (2) platelet count > 100,000 /mmm3 (3) total bililubin < 2.0 mg/dl (4) AST (GOT) < 100 U/L (5) ALT (GPT) < 100 U/L (6) serum creatinin < twice of upper limit of normal range 5) with informed consent from patient

Exclusion criteria

Exclusion criteria: 1) with rejection from patient 2) inproper for registrtion judged by medical doctor

Design outcomes

Primary

Measure	Time frame
postoperative recurrece-free survival	—

Secondary

Measure	Time frame
overall survival recurrent site and recurrent type	—

Countries

Japan

Contacts

Public ContactCheng-long Huang

Kitano hospital Department of Thoracic Surgery

chuang@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026